Sanofi will return development and commercialization rights for Afrezza inhaled insulin to MannKind after disapponting sales, and MannKind says that it is considering strategic options for the product. Afrezza was approved by the FDA in June 2014.
According to MannKind, The parties will promptly commence transition discussions in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90-180 days.”
Sanofi launched Afrezza in the US in February 2015. The company paid MannKind $150 million upfront for the US rights to the product, and the deal included a potential $775 million in milestone payments.
Read the MannKind press release.
